1:10 Stock Split Ahead: Record Date To Be Declared Soon; Do You Own Specialty Chemical Stock?

Sudarshan Pharma Industries' shares were the subject of attention on Tuesday due to the scrip's upward trending price action. In contrast to its previous close of Rs 415, the shares started at Rs 427.45 per on the BSE. The spike follows a 1:10 stock split approved by the corporation's board of directors. During their meeting on September 30, 2024, the Board of Directors recently discussed and approved splitting the company's one equity share, which had a face value of Rs. 10/-each fully paid-up, into ten equity shares of Sudarshan Pharma Industries, each of which had a face value of Rs. 1/-each fully paid-up.

On October 14, 2024, the Sudarshan Pharma Industries Board of Directors approved the acquisition of 2,09,100 equity shares of Ishwari Healthcare Private Limited at a price of Rs. 10/-each, which is equal to 51.00% of the company's paid-up equity share capital, as well as the execution of a share purchase agreement. After the deal closes, Ishwari Healthcare will become part of Sudarshan Pharma as a subsidiary.

The acquisition of Rs.2,60,00,000/- will be finalized by 31st October 2024 as per Sudarshan Pharma Industries.

On January 31, 2011, Ishwari Healthcare Private Limited was established. Ayurvedic, homoeopathic, herbal, unani, siddha, biochemi, naturopathy, and other products, instruments, apparatus, and devices related to all branches of medicine, surgery, and healthcare, including cardiology, ophthalmology, and neurology, are all produced, processed, managed, and traded by Ishwari Healthcare Private Limited. It also deals with descriptions, specifications, strengths, and applications of pharmaceutical, chemical, and healthcare products of medicaments in all its branches. All kinds of medical and surgical tools, equipment, products, products, instruments, apparatus, and gadgets pertaining to all areas of medicine, surgery, and healthcare are dealt with by Ishwari Healthcare Private Limited.

Recently the Board of Directors at their meeting held on 30th September 2024 had considered and approved a sub-division / split of the company's 1 equity share having a face value of Rs.10/- each fully paid-up, into 10 equity shares of Sudarshan Pharma Industries having face value of Re.1/- each fully paid-up, subject to the approval of shareholders and such other approvals as may be required. By capitalising the company's capital reserves, the corporation issued 57,34,489 equity shares as bonus shares to its current shareholders in a 2:1 ratio over the preceding year. The firm offered 68,62,400 equity shares under the SME IPO last year on March 22, 2023. These shares were listed on the BSE on the same day, 2023, with BSE Scrip Code 543828. The share premium account has been debited for the associated transaction fees.

The Mumbai-based company Sudarshan Pharma Industries Ltd. announced the creation of Sudarshan Maven Pharma Private Limited (Sudarshan Maven), its newest subsidiary. With a compound annual growth rate (CAGR) of 37%, Sudarshan Pharma has had remarkable profit growth over the last five years. A significant addition to Sudarshan Pharma's portfolio is the recently established subsidiary, Sudarshan Maven Pharma. Seventy thousand equity shares, priced at Rs 10 apiece, or seventy percent of Sudarshan Maven's subscribed capital have been subscribed to by the parent firm. Currently, Sudarshan Maven is permitted to own an equity share capital of Rs 25,00,000, which would be divided into 2,50,000 shares at a value of Rs 10.

Based in Mumbai, India, Sudarshan Pharma is a well-known pharmaceutical manufacturer and company.